ProKidney Corp. (NASDAQ:PROK) has reported that its Senior Vice President of Regulatory Development, Darin J. Weber, sold a total of 84,403 shares of company stock in two separate transactions. The first sale, on April 1, 2024, involved 300 shares at a price of $1.69 per share. The second and larger transaction on April 12 saw Weber sell 84,103 shares at a weighted average price of $1.73 per share, with individual sale prices ranging from $1.69 to $1.77.
The total value of the shares sold by Weber amounted to approximately $146,005. These transactions were executed automatically under a Rule 10b5-1 trading plan, which Weber had adopted on November 20, 2023. This plan allows company insiders to set up a predetermined schedule for buying and selling securities to avoid any accusations of insider trading.
Following these sales, Weber's holdings in ProKidney Corp. decreased, but he still retains 189,670 shares. ProKidney Corp., based in Winston-Salem, North Carolina, operates in the biotechnology industry, focusing on biological products.
Investors and followers of ProKidney Corp. can request detailed information about the exact number of shares sold at each price point within the reported range by contacting the company directly. The transactions were disclosed in compliance with SEC requirements, and the full details can be accessed through the SEC's filing system.
InvestingPro Insights
Amid the news of the insider sale by ProKidney Corp.'s Senior Vice President of Regulatory Development, Darin J. Weber, investors may be seeking a deeper understanding of the company's financial health and market performance. InvestingPro data reveals a market capitalization of $479.33 million, indicating the size of the company in the competitive biotech landscape. The negative P/E ratio of -2.51, which worsens to -9.51 when adjusted for the last twelve months as of Q4 2023, suggests that the company is not currently generating profits relative to its share price.
Despite the insider sale, ProKidney Corp.'s stock price has shown some recovery in the short term, with a one-month price total return of 4.26%. However, the stock has faced significant challenges over a longer period, with a six-month price total return of -49.31% and a one-year price total return of -88.05%. This performance aligns with the InvestingPro Tip that the stock price has fallen significantly over the last year.
From a strategic standpoint, ProKidney Corp. has been actively managing its share structure, as noted in the InvestingPro Tip that management has been aggressively buying back shares. This could be a sign of confidence from management in the company's future prospects or an attempt to support the share price. Additionally, the company's liquid assets exceed its short-term obligations, which might provide some financial flexibility in the near term.
For investors interested in a comprehensive analysis of ProKidney Corp., there are additional InvestingPro Tips available, which can be accessed at: https://www.investing.com/pro/PROK. These tips may provide valuable insights into the company's financial position, market performance, and future expectations. To further enrich your research, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a total of 11 InvestingPro Tips that could inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.